A2A Pharmaceuticals, Inc.'s Form 4 filing
Biomea Fusion, Inc. (BMEA) · filed Aug 19, 2022
- Accession no.
- 0001859061-22-000002
- Filed
- Aug 19, 2022
- Trade date
- Aug 16, 2022
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $425.6K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| A2A Pharmaceuticals, Inc.CIK 0001859061 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 | Common Stock | PPurchaseDisposed | −30,684 | $13.87 | −$425,587.08 | 4,300,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.